Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Equitable Trust Co.

Equitable Trust Co. increased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 33.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,282 shares of the medical research company’s stock after purchasing an additional 576 shares during the quarter. Equitable Trust Co.’s holdings in Charles River Laboratories International were worth $539,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of CRL. Private Advisor Group LLC boosted its position in shares of Charles River Laboratories International by 15.4% during the 1st quarter. Private Advisor Group LLC now owns 1,331 shares of the medical research company’s stock worth $378,000 after acquiring an additional 178 shares in the last quarter. Panagora Asset Management Inc. boosted its position in shares of Charles River Laboratories International by 236.5% in the 1st quarter. Panagora Asset Management Inc. now owns 2,722 shares of the medical research company’s stock valued at $773,000 after purchasing an additional 1,913 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of Charles River Laboratories International by 6.6% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,752 shares of the medical research company’s stock valued at $1,917,000 after purchasing an additional 418 shares during the period. Great West Life Assurance Co. Can boosted its position in shares of Charles River Laboratories International by 0.4% in the 1st quarter. Great West Life Assurance Co. Can now owns 25,049 shares of the medical research company’s stock valued at $7,465,000 after purchasing an additional 107 shares during the period. Finally, Raymond James Trust N.A. boosted its position in shares of Charles River Laboratories International by 33.7% in the 1st quarter. Raymond James Trust N.A. now owns 1,525 shares of the medical research company’s stock valued at $433,000 after purchasing an additional 384 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on CRL. Argus upped their price objective on Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, March 18th. TheStreet upgraded Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. Robert W. Baird upped their price target on Charles River Laboratories International from $252.00 to $268.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. Evercore ISI upped their price target on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. Finally, Guggenheim cut Charles River Laboratories International from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $253.23.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the transaction, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at $626,155.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP William D. Barbo sold 4,050 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the sale, the vice president now directly owns 22,879 shares of the company’s stock, valued at $5,685,431.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the sale, the executive vice president now directly owns 2,596 shares in the company, valued at $626,155.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 14,932 shares of company stock valued at $3,693,663. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Price Performance

CRL stock opened at $254.90 on Tuesday. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00. The stock’s fifty day simple moving average is $250.34 and its 200-day simple moving average is $218.86. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $13.13 billion, a price-to-earnings ratio of 27.68, a price-to-earnings-growth ratio of 1.98 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.07. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The business’s quarterly revenue was down 7.9% on a year-over-year basis. During the same period last year, the company posted $2.98 EPS. Equities research analysts expect that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).